

TECHNICAL BULLETIN

Valuable information regarding Medi-Span® applications

AT A GLANCE

Audience

Developers and end-users of MDDB, Canadian MDDB, Canadian Drug File v2, DIB, Medi-Span Price Rx, MED-File, MED-File v2, SDDB, Medi-Span Clinical API, Medi-Span Clinical Via Web Services, and Global Drug Database

Abstract

Planned GPI changes to the GPI/TCS, Enhancing Consistency in Methylphenidate Extended-Release Classification, Improving Consistency for Sublingual Tablet GPIs, Indication-Based Refinements for Tolvaptan and Lenacapavir

System Impact

Yes

Customer Support

US/CAN: medispan-support@wolterskluwer.com

International:

ce-global@medispan-support@wolterskluwer.com

Announcing GPI/TCS Changes

Purpose

The purpose of this technical bulletin is to provide details regarding planned changes to our Generic Product Identifiers (GPIs) and Therapeutic Classification System (TCS).

This technical bulletin is for developers and end-users of Master Drug Data Base (MDDB), Canadian Master Drug Data Base (Canadian MDDB), Canadian Drug File v2, The Drug Information Bridge (DIB), Medi-Span Price Rx, Medi-Span Electronic Drug File (MED-File), Medi-Span Electronic Drug File v2 (MED-File v2), Standard Drug Data Base (SDDB), Medi-Span Clinical API, Medi-Span Clinical Web Services, and Global Drug Database.

Note: The changes to the GPIs and TCS noted in this bulletin are effective on or after the **March 23, 2026** daily drug file releases. Weekly, monthly (including mapping service subscribers), semi-monthly, and quarterly customers will see these revisions with their **April 1, 2026** releases. A listing of all the GPI changes (see the [GPI Changes](#) section on page 4) and an explanation of the optionally available electronic file layout (see the [Electronic File of GPI Changes](#) section on page 11) are provided in this bulletin.

Abstract

Please note the following important information concerning the GPI changes:

- **The GPI and TCS will have planned changes effective on or after the March 23, 2026 daily drug file or Medi-Span Price Rx releases.**
- **Medi-Span is updating methylphenidate extended-release classifications to help improve global consistency and reliability. This refresh addresses customer feedback on dosing frequency, resolves GPI assignment variability within controlled delivery products, and clarifies therapeutic equivalence for generics with differing release mechanisms.**
- **Medi-Span has standardized dosage form classifications by updating desmopressin and levomefolate GPIs previously listed as disintegrating tablets with a sublingual route to the unified dosage form tablet sublingual.**
- **Indication-level specificity typically requires supplemental data sources, but certain cases warrant targeted refinements within the GPI/TCS framework. Upcoming changes include creating a new TC10 category for tolvaptan products indicated for hyponatremia and new GPIs for lenacapavir prophylaxis-only products to help improve clarity for workflows that rely on indication context.**

System Impact

Review these changes to determine what impact, if any, they may have on your application(s).

Planned GPI Changes

With the upcoming GPI changes, a number of NDC/UPC/HRIs or other drug product identifiers will be linked to newly created GPI and/or different existing GPI values.

The improved categorization of these drug products is anticipated to provide a positive impact if your applications include drug formulary and therapeutic alternative applications.

Generally, a GPI does not change for an NDC/UPC/HRI or any other drug product identifier. However, if the TCS is altered, it may be reassigned to help maintain the integrity and usefulness of the system, or it may also be reassigned if a dosage form or strength designation for an ingredient needs refinement. Lastly, it may change if there is a correction to the original GPI assignment.

Users who subscribe to offerings that are updated daily will begin to see these revisions on or after **March 23, 2026**. Weekly, monthly, semi-monthly, and quarterly customers will see these revisions with their **April 1, 2026** releases.

Medi-Span Price Rx users who include the GPI in subset definitions must reevaluate subset definitions that might potentially be affected by information displayed in the GPI Planned Changes Report (available by Alerts). Subsets may need to be changed when the new GPI data is linked to NDC/UPC/HRIs on or after **March 23, 2026**.

A new Electronic File of GPI changes that are contained in this technical bulletin is available via the Medi-Span website, at <https://wds.medispan.com>. Login with your username and password, select the “Documentation” option, then select “General Documentation,” and finally select the “Drug File Reports” folder. If you have not already obtained access to the website, please contact Customer Support to register and obtain a Web Delivery login username and password.

Note: Some updates to GPIs that affect clinical information will continue to be made without advanced notice. For U.S. and Canada, these changes are published in weekly versions of *DataFacts*.

Note For US Customers: Not every GPI change will impact the US marketplace. For changes listed as “splits” (COMPLETE REPLACE CODE = “N”), we encourage you to use the “NDCs affected by GPI Changes” Excel file, which will be available on the Medi-Span website by the end of January 2026 and announced in *DataFacts*. This file will indicate which NDC/UPC/HRIs (if any) will be affected by the GPI Change Plan.

The file will also be updated once in the week prior to the implementation of the GPI Change Plan to account for new NDCs entering the marketplace. Any applicable US NDC/UPC/HRIs added after the report is generated will not be included. In this report, US NDC/UPC/HRIs with GPIs that are “split” are only included if their GPI will change.

Enhancing Consistency in Methylphenidate Extended-Release Classification

As part of our ongoing efforts to improve product-level consistency across international markets, Medi-Span is refreshing the methylphenidate segment within the Drug File. This update addresses:

- Customer feedback: Reports of dosing frequency discrepancies, especially for international products like *Medikinet MR*, which supports 1-2 times daily dosing.
- GPI Assignment Variability: Inconsistencies within the Controlled Delivery (CD) category, where products differ in IR:ER ratios, release mechanisms, and dosing schedules.
- Therapeutic Equivalence Concerns: BX-rated generics of *Concerta* that use different release mechanisms (diffusion vs. osmotic), requiring clearer classification for reliable clinical decision support.

Improving Consistency for Sublingual Tablet GPIs

To help ensure consistency and reliability in dosage form representation, Medi-Span will update GPIs previously classified as tablet disintegrating with a sublingual route to the standardized dosage form tablet sublingual. A disintegrating tablet placed under the tongue functions identically to a sublingual tablet, so this change eliminates redundancy and improves clarity across the Drug File. This update affects desmopressin and levomefolate products.

Indication-Based Refinements for Tolvaptan and Lenacapavir

The GPI, along with the Therapeutic Classification System (TCS), organizes products based on attributes such as active ingredient, route, dosage form, strength, and broad therapeutic class. It is not designed to function as an indications database. While the GPI supports therapeutic grouping, indication-level specificity requires supplemental data sources like the Indications File.

However, certain scenarios - where indication differences materially affect prescribing and workflow integrity - warrant targeted refinements within the GPI/TCS framework:

Tolvaptan (Samsca vs. Jynarque)

Both products share the same active ingredient and therapeutic class (Selective Vasopressin V2-Receptor Antagonists), but their FDA-approved indications differ significantly: hyponatremia vs. autosomal dominant polycystic kidney disease (ADPKD). To reduce ePrescribing ambiguity and support indication-specific safeguards, we will introduce a new TC10 category for “Tolvaptan (Hyponatremia)” during the March 2026 Planned GPI Change cycle. This approach avoids a full GPI restructure while improving clarity for customers.

Lenacapavir (Yeztugo vs. Sunlenca)

The antiretroviral area of the TCS is not designed to split products by prophylaxis versus treatment, because many HIV drugs are approved for both uses. This approach maintains structural consistency and avoids unnecessary fragmentation.

However, Yeztugo (HIV prevention) and Sunlenca (HIV treatment) present a unique challenge: they share a GPI despite having mutually exclusive indications and clinical roles. To better support workflows that rely on indication context, we are introducing new GPIs specifically labeled for lenacapavir prophylaxis-only products.

This refinement is an exception to our standard TCS design principles, implemented in response to customer feedback and to improve clarity for use-case-specific processes such as drug-disease screening and regimen management.

GPI Changes

The following table lists the planned changes to GPI and Therapeutic Classes. A description of each column name is provided after the table in the *File Layout Descriptions* section.

The column **OLD GPI USED IN U.S.** reflects 14-character OLD GPI values that are used in U.S. products when the products are either active or 48-months inactive from the time that this table was created (12/29/2025). If an OLD GPI Used in U.S. has a Yes denoted, then that OLD GPI value is currently being used in a U.S. product. Please note that this does not always imply that a U.S. product will be moving from the OLD to the NEW GPI in the case of GPI splits. This attribute is specific to Record Code Values of '5' (Full GPI).

The column NEW GPI may include a GPI that already exists in the database but is a new GPI for a specific product. The GPI represented in the NEW GPI column may or may not be used for a U.S. product.

Additionally, an Excel spreadsheet of the active and 48-months inactive U.S. NDC/UPC/HRIs on file currently affected by these changes is anticipated to be available via the Medi-Span website at <https://wds.medispan.com> by the end of January 2026 and will be announced in *DataFacts*. Any applicable U.S. NDC/UPC/HRIs added to the files after the report is generated in January will not be included in this table. The spreadsheet will include the U.S. NDC/UPC/HRIs, drug name, current GPI, and the projected new GPI as of **March 23, 2026**.

In this report, U.S. NDC/UPC/HRIs having GPIs that are “split” (for example, some NDC/UPC/HRIs under the GPI may go to one or more new GPIs while other NDC/UPC/HRIs remain the same as before the split) are only included in the report if their GPI has changed. Contact Customer Support at medispan-support@wolterskluwer.com for access to the Medi-Span website.

Note: All GPIs affected by these changes are reported in the Old GPI column below. **Your current file may not contain all GPIs found in this field.** Some GPIs listed may be associated with products NOT found in the U.S. or with products that have become inactive more than 24 to 48 months.

GPI Changes Effective March 23, 2026

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
02500040202110	5	02500040202115	5	N	B	Ceftobiprole Medocaril for IV Soln 667 MG	Yes
12101555200350	5	12101555200351	5	N	B	Lenacapavir Sodium Tab 300 MG (Prophylaxis)	Yes
12101555202030	5	12101555202031	5	N	B	Lenacapavir Sodium Subcut Soln 463.5 MG/1.5ML (Prophylaxis)	Yes
1710002076	4	1710002074	4	N	A	Influenza A (H5N1) Monovalent Surface Antigen Adjuv Vaccine	
1710002076E6	7	1710002074E6	7	Y	A	Influenza A (H5N1) Monoval Surface Antigen Vac Susp Pref Syr	
1710002076E620	5	1710002074E620	5	Y	A	Influenza A(H5N1) Monoval Surf Ant Adj Susp Pref Syr 0.5 ML	
1710008500	4	1710008415	4	N	A	Smallpox & Monkeypox Vaccine, Live, Replicating	
171000850021	7	171000841521	7	N	A	Smallpox & Monkeypox Vac, Live, Rep Reconstituted Solution	
17100085002150	5	17100084152110	5	N	A	*Smallpox & Monkeypox Vac, Live, Rep For Percutaneous Inj***	Yes
21170070002020	5	21990002722021	5	A	A	Trastuzumab (w/ Hyaluronidase) Inj Soln 600 MG/5ML	
21200050002126	5	21200050006460	5	Y	B	Mitomycin (w/ Hydrogel) For Intravesical Soln 2 x 40 MG Kit	Yes
21200050002160	5	21200050006430	5	Y	B	Mitomycin (w/ Hydrogel) For Pyelocalyceal Soln 2 x 40MG Kit	Yes
21351860002070	5	21990002642070	5	A	A	Rituximab (w/Hyaluronidase) Subcutaneous Soln 1400 MG/11.7ML	
21354027002050	5	21990002152021	5	A	A	Daratumumab (w/ Hyaluronidase) Inj Soln 1800 MG/15ML	
21651035401820	5	21651035401830	5	Y	B	Idecabtagene Vicleucel IV Susp 510,000,000 CELLS	Yes
2199000255	4	2199000355	4	A	A	Pertuzumab-Trastuzumab-Hyaluronidase-zzxf	
219900025520	7	219900035520	7	A	A	Pertuzumab-Trastuzumab-Hyaluronidase-zzxf Solution	
21990002552020	5	21990003552021	5	A	A	Pertuzumab-Trastuzumab (w/ Hyaluronidase) Inj 60-60 MG/ML	
25200050005320	5	25200050005324	5	N	B	Levonorgestrel IUD 21 MCG/DAY (Initial) (52 MG Total)	Yes
26000040002020	5	26000040002015	5	N	B	Progesterone Solution for Subcutaneous Inj 25 MG/1.112ML	
26000040002020	5	26000040002016	5	N	B	Progesterone Solution Inj 25 MG/1.112ML	
26000040002022	5	26000040002016	5	N	B	Progesterone Solution Inj 25 MG/1.112ML	
302010101072	7	302010101007	7	N	B	Desmopressin Acetate Sublingual Tablet	
30201010107206	5	30201010100708	5	A	B	Desmopressin Acetate Sublingual Tab 25 MCG (Base Equiv)	
30201010107210	5	30201010100713	5	A	B	Desmopressin Acetate Sublingual Tab 50 MCG (Base Equiv)	
30201010107215	5	30201010100720	5	A	B	Desmopressin Acetate Sublingual Tab 60 MCG (Base Equivalent)	
30201010107225	5	30201010100730	5	A	B	Desmopressin Acetate Sublingual Tab 100 MCG (Base Equiv)	
30201010107230	5	30201010100740	5	A	B	Desmopressin Acetate Sublingual Tab 120 MCG (Base Equiv)	
30201010107240	5	30201010100750	5	A	B	Desmopressin Acetate Sublingual Tab 240 MCG (Base Equiv)	
3045406000	4	3045406060	4	N	A	Tolvaptan (Hyponatremia)	

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
304540600003	7	304540606003	7	N	A	Tolvaptan (Hyponatremia) Tablet	
30454060000310	5	30454060600310	5	N	A	Tolvaptan (Hyponatremia) Tab 7.5 MG	
30454060000320	5	30454060600320	5	N	A	Tolvaptan (Hyponatremia) Tab 15 MG	Yes
30454060000330	5	30454060600330	5	N	A	Tolvaptan (Hyponatremia) Tab 30 MG	Yes
3090620000	3	3090620000	3	C	D	*Familial Chylomicronemia Syndrome (FCS) - Agents***	
3520002010E520	5	3520002010E522	5	N	B	Lidocaine HCl (Cardiac) IV PF Soln Pref Syr 50 MG/5ML(1%)	Yes
38900040002030	5	38000032002040	5	A	A	Epinephrine Inj 1 MG/ML	Yes
38900040002060	5	38000032002040	5	A	A	Epinephrine Inj 1 MG/ML	Yes
38900040052020	5	38000032052010	5	A	A	Epinephrine Bitartrate Inj 1 MG/ML (Base Eq)	
38900040052030	5	38000032052020	5	A	A	Epinephrine Bitartrate Inj 1 MG/10ML (0.1 MG/ML) (Base Eq)	
441000750020	7	441000750025	7	N	B	Revefenacin Nebulizing Solution	
44100075002020	5	44100075002530	5	Y	B	Revefenacin Nebulizing Solution 175 MCG/3ML	Yes
4610000000	2	4610000000	2	C	D	*Electrolyte-based Osmotic Laxatives**	
4610000000	3	4610000000	3	C	D	*Electrolyte-based Osmotic Laxatives***	
4610990000	3	4610990000	3	C	D	*Electrolyte-based Osmotic Laxative Mixtures***	
4610990200	6	4610990200	6	C	D	Electrolyte-based Osmotic Laxative Mixtures - 2 Ingredient	
4610990210	4	4610990212	4	A	A	Sodium Phosphate Monobasic-Sodium Phosphate Dibasic	
461099021020	7	461099021220	7	A	A	Sodium Phosphate Monobasic-Sodium Phosphate Dibasic Solution	
46109902102000	5	46109902122000	5	A	A	*Sodium Phosphate Monobasic-Sodium Phos Dibasic - Soln***	
461099021030	7	461099021230	7	A	A	Sodium Phosphate Monobasic-Sodium Phosphate Dibasic Packet	
46109902103000	5	46109902123000	5	A	A	*Sodium Phosphate Monobasic-Sodium Phos Dibasic - Pack***	
461099021051	7	461099021251	7	A	A	Sodium Phosphate Monobasic-Sodium Phosphate Dibasic Enema	
46109902105100	5	46109902125100	5	A	A	*Sodium Phosphate Monobasic-Sodium Phos Dibasic Enema***	Yes
46109902105110	5	46109902125110	5	A	A	*Sodium Phosphate Monobasic & Dibasic Enema (Pediatric)***	Yes
4610990300	6	4610990300	6	C	D	Electrolyte-based Osmotic Laxative Mixtures - 3 Ingredient	
46400010001700	5	46400010001750	5	N	B	Mineral Oil (Bulk)	Yes
502800200063	7	5028002000B2	7	N	B	Aprepitant Capsule Therapy Pack	
50280020006320	5	5028002000B220	5	Y	B	Aprepitant Capsule Therapy Pack 80 & 125 MG	Yes
59100010100920	5	59100010100905	5	N	B	Haloperidol Oral Liquid 0.2 MG/ML	
60201025042004	5	60201025122008	5	N	A	Midazolam HCl 50 MG/50ML-Sodium Chloride 0.9% IV Soln	Yes
60201025042008	5	60201025122012	5	N	A	Midazolam HCl 100 MG/100ML in NaCl 0.9% IV Soln	Yes
61400020100205	5	61400020100206	5	N	B	Methylphenidate HCl Cap ER 5 MG (MR)	
61400020100210	5	61400020100211	5	N	B	Methylphenidate HCl Cap ER 10 MG (MR)	Yes
61400020100210	5	61400020107010	5	N	B	Methylphenidate HCl Cap ER 24HR 10 MG (LA)	Yes
61400020100210	5	61400020107055	5	N	B	Methylphenidate HCl Cap ER 24HR 10 MG (XR)	Yes
61400020100215	5	61400020100216	5	N	B	Methylphenidate HCl Cap ER 15 MG (MR)	
61400020100215	5	61400020107060	5	N	B	Methylphenidate HCl Cap ER 24HR 15 MG (XR)	
61400020100220	5	61400020100221	5	N	B	Methylphenidate HCl Cap ER 20 MG (MR)	Yes

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
61400020100220	5	61400020107020	5	N	B	Methylphenidate HCl Cap ER 24HR 20 MG (LA)	Yes
61400020100220	5	61400020107065	5	N	B	Methylphenidate HCl Cap ER 24HR 20 MG (XR)	Yes
61400020100230	5	61400020100231	5	N	B	Methylphenidate HCl Cap ER 30 MG (MR)	Yes
61400020100230	5	61400020107030	5	N	B	Methylphenidate HCl Cap ER 24HR 30 MG (LA)	Yes
61400020100230	5	61400020107070	5	N	B	Methylphenidate HCl Cap ER 24HR 30 MG (XR)	Yes
61400020100240	5	61400020100241	5	N	B	Methylphenidate HCl Cap ER 40 MG (MR)	Yes
61400020100240	5	61400020107040	5	N	B	Methylphenidate HCl Cap ER 24HR 40 MG (LA)	Yes
61400020100240	5	61400020107075	5	N	B	Methylphenidate HCl Cap ER 24HR 40 MG (XR)	Yes
61400020100250	5	61400020100251	5	N	B	Methylphenidate HCl Cap ER 50 MG (MR)	Yes
61400020100250	5	61400020107080	5	N	B	Methylphenidate HCl Cap ER 24HR 50 MG (XR)	Yes
61400020100260	5	61400020100261	5	N	B	Methylphenidate HCl Cap ER 60 MG (MR)	Yes
61400020100260	5	61400020107048	5	N	B	Methylphenidate HCl Cap ER 24HR 60 MG (LA)	Yes
61400020100260	5	61400020107085	5	N	B	Methylphenidate HCl Cap ER 24HR 60 MG (XR)	Yes
61400020100280	5	61400020100281	5	N	B	Methylphenidate HCl Cap ER 80 MG (MR)	
61400020100280	5	61400020107089	5	N	B	Methylphenidate HCl Cap ER 24HR 80 MG (XR)	
61400020100465	5	61400020100425	5	N	B	Methylphenidate HCl Tab ER Diffusion 27 MG	Yes
61400020100470	5	61400020100430	5	N	B	Methylphenidate HCl Tab ER Diffusion 36 MG	Yes
61400020100475	5	61400020100435	5	N	B	Methylphenidate HCl Tab ER Diffusion 45 MG	Yes
61400020100480	5	61400020100440	5	N	B	Methylphenidate HCl Tab ER Diffusion 54 MG	Yes
61400020100485	5	61400020100445	5	N	B	Methylphenidate HCl Tab ER Diffusion 63 MG	Yes
61400020100490	5	61400020100450	5	N	B	Methylphenidate HCl Tab ER Diffusion 72 MG	Yes
61400020107518	5	61400020100460	5	N	B	Methylphenidate HCl Tab ER Osmotic Release (OSM) 18 MG	Yes
6210001000	4	6210000507	4	N	A	Nicotine Betadex	
621000100007	7	621000050707	7	N	A	Nicotine Betadex Sublingual Tablet	
62100010000710	5	62100005070710	5	Y	A	Nicotine Betadex SL Tab 2 MG	
66100060000305	5	66100060100304	5	N	A	Naproxen Sodium Tab 250 MG	Yes
6629003000F515	5	6629003000F516	5	Y	B	Etanercept Subcutaneous Auto-Injector Inj Kit 25 MG/0.5ML	
6629003000F530	5	6629003000F531	5	Y	B	Etanercept Subcutaneous Auto-Injector Inj Kit 50 MG/ML	
6629003000F830	5	6629003000F831	5	Y	B	Etanercept Subcutaneous Prefilled Syringe Kit 50 MG/ML	
78441000002005	5	78441000001810	5	A	B	*Pediatric Multiple Vitamin w/ Fluoride Susp 0.25 MG/ML***	Yes
78441000002010	5	78441000001820	5	A	B	*Pediatric Multiple Vitamins w/ Fluoride Susp 0.5 MG/ML***	Yes
78500000000100	5	78500000000100	5	C	D	*Specialty Vitamin Product Cap**	Yes
78500000000300	5	78500000000300	5	C	D	*Specialty Vitamin Product Tab**	Yes
78500000000400	5	78500000000400	5	C	D	*Specialty Vitamin Product Tab ER**	
78500000000600	5	78500000000600	5	C	D	*Specialty Vitamin Product EC Tab**	Yes
78500000000800	5	78500000000800	5	C	D	*Specialty Vitamin Product Effer Tab**	Yes
78500000000900	5	78500000000900	5	C	D	*Specialty Vitamin Product Liquid**	

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
78500000003000	5	78500000003000	5	C	D	*Specialty Vitamin Product Packet**	
78500000006300	5	78500000006300	5	C	D	*Specialty Vitamin Product Combo Pak**	Yes
81200000000900	5	81200000000910	5	N	B	*Nutritional Supplement Liquid (Enteral)**	Yes
812500552072	7	812500552007	7	N	B	Levomefolate Glucosamine Sublingual Tablet	
81250055207220	5	81250055200720	5	Y	B	Levomefolate Glucos Sublingual Tab 400 MCG (Folate Equiv)	
82100010000715	5	82100010007270	5	N	B	Cyanocobalamin Orally Disintegrating Tab 2500 MCG	Yes
82100010000730	5	82100010007280	5	N	B	Cyanocobalamin Orally Disintegrating Tab 5000 MCG	Yes
8420005020	4	8420005010	4	A	A	Thrombin (Recombinant)	
842000502021	7	842000501021	7	A	A	Thrombin (Recombinant) Reconstituted Solution	
84200050202120	5	84200050102113	5	Y	A	Thrombin (Recombinant) For Soln 6000 Unit	
84200050202130	5	84200050102134	5	Y	A	Thrombin (Recombinant) For Soln 24000 Unit	
86655060302022	5	86655060302020	5	A	B	Ranibizumab-eqrn Intravitreal Inj 0.5 MG/0.05ML (10 MG/ML)	
86655060502050	5	86655060502020	5	A	B	Ranibizumab-nuna Intravitreal Inj 0.5 MG/0.05ML (10 MG/ML)	
86655060602020	5	86655060602015	5	A	B	Ranibizumab-l153 Intravitreal Inj 0.5 MG/0.05ML (10 MG/ML)	
86655060612020	5	86655060612015	5	A	B	Ranibizumab-h124 Intravitreal Inj 0.5 MG/0.05ML (10 MG/ML)	
86720020001620	5	86720020001621	5	N	B	Cyclosporine (Ophth) Emulsion 0.05% (PF)	Yes
86720020001630	5	86720020001631	5	N	B	Cyclosporine (Ophth) Emulsion 0.1% (PF)	Yes
90109902403710	5	90109902403750	5	Y	B	Neomycin-Hydrocortisone Acetate Cream 0.5-0.5%	
90109902403720	5	90109902403760	5	Y	B	Neomycin-Hydrocortisone Acetate Cream 0.5-1%	
90109902404210	5	90109902404250	5	Y	B	Neomycin-Hydrocortisone Acetate Oint 0.5-0.5%	
90109902404220	5	90109902404260	5	Y	B	Neomycin-Hydrocortisone Acetate Oint 0.5-1%	
90109902404224	5	90109902404265	5	Y	B	Neomycin-Hydrocortisone Acetate Oint 0.5-1.5%	
90109902404230	5	90109902404275	5	Y	B	Neomycin-Hydrocortisone Acetate Oint 0.5-2.5%	
90210030004020	5	90210030304020	5	N	A	Diclofenac Sodium Gel 1% (1.16% Diethylamine Equiv)	
90210030104020	5	90210030304020	5	N	A	Diclofenac Sodium Gel 1% (1.16% Diethylamine Equiv)	
9093990000	3	9093000000	3	A	A	*Scar Treatment Products***	
9093990200	6	9093000000	6	A	A	Scar Treatment Products	
9093990220	4	9093000000	4	A	A	Scar Treatment Products	
909399022059	7	909300000059	7	A	A	Scar Treatment Products Patch	
90939902205920	5	90930000005900	5	A	A	*Scar Treatment Products - Patch**	Yes
9093990235	4	9093000000	4	A	A	Scar Treatment Products	
909399023564	7	909300000064	7	A	A	Scar Treatment Products Kit	
90939902356420	5	90930000006400	5	A	A	*Scar Treatment Products - Kit**	Yes
92200020001520	5	92200020001510	5	A	B	*Iodine Tincture**	Yes
92200020001530	5	92200020001510	5	A	B	*Iodine Tincture**	
93000010100900	5	93000010101825	5	N	B	Charcoal Activated Susp 5 GM/24 ML	Yes
93000010100900	5	93000010101835	5	N	B	Charcoal Activated Susp 5 GM/48 ML	Yes
9300001020	4	9300001020	4	C	D	Charcoal Activated (with Sorbitol)	
930000102009	7	930000102009	7	C	D	Charcoal Activated (with Sorbitol) Liquid	

OLD GPI	OLD REC CD	NEW GPI	NEW REC CD	COMPLETE REPLACE CODE	REASON CODE	NEW GPI NAME	OLD GPI USED IN US†
93000010200900	5	93000010200900	5	C	D	*Charcoal Activated (with Sorbitol) Liquid*	
930000102018	7	930000102018	7	C	B	Charcoal Activated (with Sorbitol) Suspension	
93000010201800	5	93000010201822	5	N	B	Charcoal Activated (with Sorbitol) Susp 4.8 GM/24 ML	Yes
93000010201800	5	93000010201825	5	N	B	Charcoal Activated (with Sorbitol) Susp 5 GM/24 ML	Yes
93000010201800	5	93000010201835	5	N	B	Charcoal Activated (with Sorbitol) Susp 5 GM/48 ML	Yes
94200055002115	5	94200055002116	5	N	B	Indocyanine Green For Inj Soln 25 MG	Yes
95210354000335	5	95210354000635	5	N	B	Garlic EC Tab 350 MG	Yes
95391536000750	5	95391536007260	5	N	B	Melatonin Tablet Disintegrating 10 MG	Yes
96200050000900	5	90650012000900	5	N	A	Glycerin Topical Liquid	Yes
99394050000110	5	99394050100110	5	N	A	Lenalidomide Ammonium Chloride Cap 2.5 MG	Yes
99394050000120	5	99394050100120	5	N	A	Lenalidomide Ammonium Chloride Cap 5 MG	Yes
99394050000125	5	99394050100125	5	N	A	Lenalidomide Ammonium Chloride Cap 7.5 MG	
99394050000130	5	99394050100130	5	N	A	Lenalidomide Ammonium Chloride Cap 10 MG	Yes
99394050000140	5	99394050100140	5	N	A	Lenalidomide Ammonium Chloride Cap 15 MG	Yes
99394050000145	5	99394050100145	5	N	A	Lenalidomide Ammonium Chloride Cap 20 MG	Yes
99394050000150	5	99394050100150	5	N	A	Lenalidomide Ammonium Chloride Cap 25 MG	Yes
99850000000300	5	95990266360335	5	N	A	Valerian-Lemon Balm Tab 160-80 MG	Yes

† ‘Yes’ in the OLD GPI USED IN U.S. column indicates that the OLD GPI (Record Code Values of ‘5’) is used in a U.S. product that is either active or 48 months inactive from the time that this table was created 12/29/2025. Only Record Code values of ‘5’ will reflect this code. The NEW GPI may or may not be used for a U.S. product. OLD GPI values not coded with a ‘Yes’ may be used in countries other than the U.S. or are inactive more than 48 months.

In This Section...

- [Explanation of Values and Symbols](#)
- [Electronic File of GPI Changes](#)
- [File Layout](#)
- [File Layout Descriptions](#)

Explanation of Values and Symbols

COMPLETE REPLACE CODE

For a complete description of these values, go to the [Electronic File of GPI Changes](#) section below.

Value	CMPLT-REPLACE Description
Y	REPLACEMENT: YES , this is a complete replacement of a GPI (one-to-one replacement)
A	MERGE: YES , this is a complete replacement of a GPI (many-to-one replacement)

N	SPLIT: NO , this is not a complete GPI replacement (one-to-many replacement)
C	CHANGE: Change of GPI or TCS Name only - no change of value
Blank	NEW RECORD

REASON CODE

For a complete description of these values, see the [Electronic file of GPI Changes](#) below.

Reason Code Value	Reason Description
A	Therapeutic Class or Drug Salt Revision (Changes through first 10 positions of GPI)
B	Dosage Form, Route, Strength or Other Change (changes in the last 4 positions of the GPI). Includes new Dosage Forms and Routes-of-Administration.
C	Not Used
D	TCS or GPI Description Change
E	Change due to USP Standards Revision

Electronic File of GPI Changes

A new electronic copy of the GPI changes is available via the Medi-Span website at <https://wds.medispan.com>. The following is a description of the contents of the Electronic File of GPI Changes.

The Electronic File of GPI Changes is an MS-DOS ASCII file of planned GPI revisions. The effective date of the change is found in the Effective Date field. This file is sorted on the current GPI value and REC-CD. Refer to the following File Layout section below. The GPI field corresponds to the current GPI, and the NEW-GPI field corresponds to the future GPI value (value that becomes effective at the specified effective date).

File Layout

DATAFILE NAME: GPI.CHG

8 ITEMS: STARTING IN POSITION 1

COL	ITEM NAME	WDTH	OPUT	TYP	
1	GPI	14	14	C	
15	REC-CD	1	1	C	(1,2,3,4,5,6,7 or blank)
16	NEW-GPI	14	14	C	
30	NEW-REC-CD	1	1	C	(1,2,3,4,5,6,7 or blank)
31	CMPLT-REPLACE	1	1	C	(Y,A,N,C, or blank)
32	REASON-CD	1	1	C	(A,B,C,D,E)
33	NEW-GPI-NAME	60	60	C	
93	EFF-DATE	8	10	D	(YYYYMMDD)

Note: This Electronic File of GPI changes does not identify the NDC/UPC/HRI/other drug product identifier values impacted by these changes. An Excel spreadsheet of the currently affected U.S. NDC/UPC/HRIs will be available on the Medi-Span website beginning in late January 2026. The complete listing of all affected U.S. NDC/UPC/HRIs, with their new GPIs, will be output with your **March 23, 2026** releases. Weekly, monthly, semi-monthly, and quarterly customers will see these revisions with their **April 1, 2026** releases.

File Layout Descriptions

Following is a description of each item listed in the file layout and in the GPI Changes table:

GPI (GPI) - This is the current Therapeutic Class or GPI value. The field contains 10 characters for Therapeutic Class and 14 characters for GPI.

The GPI value is not unique and may repeat for instances when a GPI goes from one to many. For GPIs that are not complete replacements, the GPI is repeated with each new GPI value that may be used for this split. **You must determine the impact of this change for your application(s).**

The Current GPI field or the NEW-GPI field may be zero-filled depending on the type of change that has

occurred. In addition, the current GPI or NEW-GPI field may only contain ten (10) positions of the GPI for REC-CD or NEW-REC-CD values of '1', '2', '3', '4', '6'. It will contain twelve (12) characters for REC-CD or NEW- REC-CD values of '7' and 14 characters for the GPI REC-CD and NEW-REC-CD values of '5'.

All GPIs affected by these changes are reported in this data element. Your current file may not contain all GPIs found in this field.

Record Code (REC-CD) - This is the current Record Code for the Therapeutic Class or GPI. This field indicates the level of the name. Therapeutic Class records have values of '1', '2', '3', '4', '6', '7'. GPI records have a value of '5'. The Record Code has the following values:

Record Code Value	Record Code Description
1	Drug Group
2	Drug Class
3	Drug Subclass
6	Drug Base Name
4	Drug Name/Drug Name Extension
7	Drug Name and Dosage Form
5	Full GPI NAME
Blank	No corresponding new TC-GPI value

New GPI (NEW-GPI) - This is the new Therapeutic Class or GPI value. The field will contain ten (10) characters for REC-CD or NEW-REC-CD values of: '1', '2', '3', '4', and '6'. It will contain twelve (12) characters for REC-CD or NEW-REC-CD values of '7' and 14 characters for the GPI REC-CD and NEW-REC-CD values of '5'. The New GPI value is not unique and may repeat for instances when a GPI goes from many to one.

New Record Code (NEW-REC-CD) - This is the new Record Code for the Therapeutic Class or GPI. This field indicates the level of the name. Therapeutic Class records have values of '1', '2', '3', '4', '6', '7'. GPI records have a value of '5'. The Record Code has the following values:

Record Code Value	Record Code Description
1	Drug Group
2	Drug Class
3	Drug Subclass
6	Drug Base Name
4	Drug Name/Drug Name Extension
7	Drug Name and Dosage Form
5	Full GPI NAME
Blank	No corresponding new TC-GPI value

Complete Replace Code (CMPLT-REPLACE) - This field is a flag to indicate if all NDC/UPC/HRIs/other drug product identifiers that have the current GPI value are assigned the NEW-GPI. Values are as follows:

CMPLT-REPLACE	
Value	CMPLT-REPLACE Description
Y	REPLACEMENT: YES , this is a complete replacement of a GPI. All NDC/UPC/HRIs/other drug product identifiers with the current GPI and associated classification records are assigned the new GPI values. Current GPI values may be deleted after the effective date of these changes. (1:1 Replacement - the GPPC will not change for these revisions.)
A	MERGE: YES , this is a complete replacement of a GPI. All NDC/UPC/HRIs/other drug product identifiers with the current GPI and associated classification records are assigned the new GPI values. Current GPI values are deleted after the effective date of these changes. (Many:1 Replacement - the GPPC may change for these revisions.)
N	SPLIT: NO , this is not a complete GPI replacement. NDC/UPC/HRIs/other drug product identifiers under this GPI may retain the current value or be changed to one of the newly created GPIs identified in the NEW-GPI field. Do not delete the current GPI value after the effective date of these changes - the current GPI value may still be used after these changes. (1:Many Replacement - NDC/UPC/HRIs/other drug product identifiers that are assigned to a different GPI after these changes will have a corresponding change in the GPPC value.)
C	CHANGE: Change of GPI or TCS Name only - no change of value. Do not delete GPI values associated with this code. (Output in this file is informational only - the GPPC will not change for these revisions.)
Blank	NEW RECORD: There is no existing record that corresponds to this value. (0:1 Replacement)

Reason Code (REASON-CD) - A code indicating the reason for the change is included in position 32. The Reason Code has the following values:

Reason Code Value	Reason Description
A	Therapeutic Class or Drug Salt Revision (Changes through first 10 positions of GPI)
B	Dosage Form, Route, Strength or Other Change (changes in the last 4 positions of the GPI). Includes new Dosage Forms and Routes-of-Administration.
C	Not Used
D	TCS or GPI Description Change
E	Change due to USP Standards Revision

New GPI Name (NEW-GPI-NAME) – This field reflects the name of the new GPI value.

Effective Date (EFF-DATE) – This field reflects the effective date of the GPI Change in YYYYMMDD format.